Type 2 Diabetes Pills: Modern Therapeutic Options
Type 2 diabetes mellitus (T2DM) is a chronic condition in which the body loses the ability to use insulin effectively. While lifestyle modification remains the foundation of treatment, most patients eventually require pharmacological support. Modern pharmacology offers a wide range of oral medications that not only control blood glucose levels but also influence body weight, cardiovascular risks, and other important aspects of health.
Metformin — the gold standard of therapy
Metformin (Glucophage, Siofor) is the first-line drug used to initiate treatment in most patients with type 2 diabetes.
Mechanism of action:
Metformin does not stimulate insulin secretion but works through other mechanisms:
- reduces glucose production by the liver (gluconeogenesis)
- decreases intestinal glucose absorption
- increases tissue sensitivity to insulin
Key benefits:
- Does not cause hypoglycemia (dangerous low blood sugar) when used as monotherapy
- Promotes weight loss or stabilization
- Improves lipid profile (reduces triglycerides and LDL cholesterol)
- Affordable and well-studied
Dosage regimen:
The initial dose is usually 500–850 mg per day, gradually increased to a maintenance dose of 1500–2000 mg/day. The maximum dose is 2550–3000 mg/day. The drug should be taken with or after meals to minimize gastrointestinal side effects.
Important precautions:
Metformin is contraindicated in severe renal impairment (creatinine clearance <60 ml/min), liver disease, chronic alcoholism, and conditions associated with hypoxia (heart or respiratory failure).
Main classes of oral glucose-lowering drugs
Modern classification identifies 10 classes of oral medications for T2DM:
| Drug Class | Mechanism of Action | Effect on Weight | Hypoglycemia Risk |
|---|---|---|---|
| Biguanides (metformin) | Reduce hepatic glucose production | Neutral / decrease | Low |
| Sulfonylureas (glibenclamide, gliclazide) | Stimulate pancreatic insulin secretion | Increase | High |
| Glinides (repaglinide) | Rapid insulin stimulation | Increase | Moderate |
| Thiazolidinediones (pioglitazone) | Increase insulin sensitivity | Increase | Low |
| Alpha-glucosidase inhibitors (acarbose) | Slow carbohydrate absorption in the intestine | Neutral | Low |
| DPP-4 inhibitors (sitagliptin, alogliptin) | Increase incretin activity | Neutral | Low |
| SGLT2 inhibitors (dapagliflozin, empagliflozin) | Promote urinary glucose excretion | Decrease | Low |
| GLP-1 receptor agonists (oral semaglutide) | Enhance insulin response, reduce appetite | Decrease | Low |
DPP-4 inhibitors (gliptins)
Drugs in this class (alogliptin, sitagliptin, saxagliptin, vildagliptin) act on the incretin system — a natural mechanism for glucose regulation. They prolong the action of hormones GLP-1 and GIP, which stimulate insulin secretion in response to food intake.
A key feature is that these drugs do not cause hypoglycemia and do not increase body weight, making them a convenient option for many patients. Alogliptin has shown effectiveness both as monotherapy and in combination with metformin.
SGLT2 inhibitors (gliflozins)
This is a relatively new class of drugs (dapagliflozin, empagliflozin, canagliflozin) that act via the kidneys: they block glucose reabsorption, allowing excess sugar to be excreted in the urine.
Additional benefits:
- Reduction in blood pressure
- Weight loss
- Proven cardio- and nephroprotection (protection of the heart and kidneys)
GLP-1 receptor agonists (including oral semaglutide)
For a long time, drugs in this class (Ozempic, Wegovy, etc.) were available only as injections. However, oral semaglutide (in Russia — Deglunorm and other analogs) is now available — the first and currently the only oral GLP-1 receptor agonist.
These drugs:
- Stimulate insulin secretion in a glucose-dependent manner (only when blood sugar is elevated)
- Reduce appetite and slow gastric emptying
- Promote significant weight loss
- Reduce cardiovascular risks
Since 2025, domestic semaglutide analogs have appeared in Russia, making this modern therapy more accessible.
Sulfonylureas
Drugs in this group (glibenclamide, gliclazide, glimepiride) stimulate the pancreas to produce more insulin. They effectively lower blood glucose but have significant drawbacks: a high risk of hypoglycemia and weight gain. Today, they are more often used as second- or third-line therapy.
Combination therapy
Many patients require not one but two or even three medications to achieve target glycated hemoglobin (HbA1c) levels. Fixed-dose combinations in a single tablet are available — for example, metformin + DPP-4 inhibitor or metformin + SGLT2 inhibitor. This improves convenience and treatment adherence.
Russian developments
It is important to note that Russian scientists are actively working on new domestic drugs. For example, researchers at the Novosibirsk Institute of Organic Chemistry are developing an innovative compound capable of simultaneously affecting glucose and cholesterol levels by acting on PPAR receptors. This drug is currently in preclinical trials and may potentially become the third registered drug of its class worldwide.
Importance of an individualized approach
The choice of an oral medication is always a joint decision between doctor and patient, taking into account many factors:
- HbA1c level and fasting glucose
- Duration of the disease
- Body weight and presence of obesity
- Kidney function
- Presence of cardiovascular diseases
- Risk of hypoglycemia (especially in elderly patients)
- Cost and availability of therapy
Important:
This information is for informational purposes only. Any changes to glucose-lowering therapy should be made only under the supervision of a healthcare provider (endocrinologist). Self-treatment of diabetes can be dangerous to life and health.
No medication replaces the need for a proper diet, physical activity, and regular blood glucose monitoring. Only a comprehensive approach allows effective management of type 2 diabetes and prevention of its complications.